Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.
Several hurdles must be overcome in order to achieve efficient and safe immunotherapy against conformational neurodegenerative diseases. In prion diseases, the main difficulty is that the prion protein is tolerated as a self protein, which prevents powerful immune responses. Passive antibody therapy...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-09-01
|
Series: | PLoS Pathogens |
Online Access: | http://europepmc.org/articles/PMC3164648?pdf=render |
id |
doaj-ca32df08f9c447578cb0a726c547035d |
---|---|
record_format |
Article |
spelling |
doaj-ca32df08f9c447578cb0a726c547035d2020-11-25T01:58:25ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742011-09-0179e100221610.1371/journal.ppat.1002216Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.Saci IkenVéronique BachyPauline GourdainAnnick LimSylvie GrégoireThomas ChaigneauPierre AucouturierClaude CarnaudSeveral hurdles must be overcome in order to achieve efficient and safe immunotherapy against conformational neurodegenerative diseases. In prion diseases, the main difficulty is that the prion protein is tolerated as a self protein, which prevents powerful immune responses. Passive antibody therapy is effective only during early, asymptomatic disease, well before diagnosis is made. If efficient immunotherapy of prion diseases is to be achieved, it is crucial to understand precisely how immune tolerance against the prion protein can be overcome and which effector pathways may delay disease progression. To this end, we generated a transgenic mouse that expresses the ß-chain of a T cell receptor recognizing a PrP epitope presented by the class II major histocompatibility complex. The fact that the constraint is applied to only one TCR chain allows adaptation of the other chain according to the presence or absence of tolerogenic PrP. We first show that transgene-bearing T cells, pairing with rearranged α-chains conferring anti-PrP specificity, are systematically eliminated during ontogeny in PrP+ mice, suggesting that precursors with good functional avidity are rare in a normal individual. Second, we show that transgene-bearing T cells with anti-PrP specificity are not suppressed when transferred into PrP+ recipients and proliferate more extensively in a prion-infected host. Finally, such T cells provide protection through a cell-mediated pathway involving IL-4 production. These findings support the idea that cell-mediated immunity in neurodegenerative conditions may not be necessarily detrimental and may even contribute, when properly controlled, to the resolution of pathological processes.http://europepmc.org/articles/PMC3164648?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Saci Iken Véronique Bachy Pauline Gourdain Annick Lim Sylvie Grégoire Thomas Chaigneau Pierre Aucouturier Claude Carnaud |
spellingShingle |
Saci Iken Véronique Bachy Pauline Gourdain Annick Lim Sylvie Grégoire Thomas Chaigneau Pierre Aucouturier Claude Carnaud Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie. PLoS Pathogens |
author_facet |
Saci Iken Véronique Bachy Pauline Gourdain Annick Lim Sylvie Grégoire Thomas Chaigneau Pierre Aucouturier Claude Carnaud |
author_sort |
Saci Iken |
title |
Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie. |
title_short |
Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie. |
title_full |
Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie. |
title_fullStr |
Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie. |
title_full_unstemmed |
Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie. |
title_sort |
th2-polarised prp-specific transgenic t-cells confer partial protection against murine scrapie. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS Pathogens |
issn |
1553-7366 1553-7374 |
publishDate |
2011-09-01 |
description |
Several hurdles must be overcome in order to achieve efficient and safe immunotherapy against conformational neurodegenerative diseases. In prion diseases, the main difficulty is that the prion protein is tolerated as a self protein, which prevents powerful immune responses. Passive antibody therapy is effective only during early, asymptomatic disease, well before diagnosis is made. If efficient immunotherapy of prion diseases is to be achieved, it is crucial to understand precisely how immune tolerance against the prion protein can be overcome and which effector pathways may delay disease progression. To this end, we generated a transgenic mouse that expresses the ß-chain of a T cell receptor recognizing a PrP epitope presented by the class II major histocompatibility complex. The fact that the constraint is applied to only one TCR chain allows adaptation of the other chain according to the presence or absence of tolerogenic PrP. We first show that transgene-bearing T cells, pairing with rearranged α-chains conferring anti-PrP specificity, are systematically eliminated during ontogeny in PrP+ mice, suggesting that precursors with good functional avidity are rare in a normal individual. Second, we show that transgene-bearing T cells with anti-PrP specificity are not suppressed when transferred into PrP+ recipients and proliferate more extensively in a prion-infected host. Finally, such T cells provide protection through a cell-mediated pathway involving IL-4 production. These findings support the idea that cell-mediated immunity in neurodegenerative conditions may not be necessarily detrimental and may even contribute, when properly controlled, to the resolution of pathological processes. |
url |
http://europepmc.org/articles/PMC3164648?pdf=render |
work_keys_str_mv |
AT saciiken th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie AT veroniquebachy th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie AT paulinegourdain th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie AT annicklim th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie AT sylviegregoire th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie AT thomaschaigneau th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie AT pierreaucouturier th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie AT claudecarnaud th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie |
_version_ |
1724969805376651264 |